A5063746102- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Sarcoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Stroke Rehabilitation and Recovery
- Hematological disorders and diagnostics
- Dementia and Cognitive Impairment Research
- Health Literacy and Information Accessibility
- Schizophrenia research and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Polyomavirus and related diseases
- Alzheimer's disease research and treatments
- Bone health and treatments
- Mobile Health and mHealth Applications
- Neuroscience of respiration and sleep
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- Dermatological and Skeletal Disorders
National Cancer Institute
2021-2025
National Institutes of Health
2021-2025
University of Virginia
2025
Center for Cancer Research
2024-2025
Office of AIDS Research
2023
Emory University
2017-2021
Winship Cancer Institute
2019
Emory University Hospital
2018
University of Michigan
2014-2017
Michigan Medicine
2015
Little is known about how regions vary in their use of thrombolysis (intravenous tissue-type plasminogen activator and intra-arterial treatment) for acute stroke. We sought to determine regional variation treatment investigate the extent which accounted by patient demographics, factors, elements stroke systems care.Retrospective cross-sectional study all fee-for-service Medicare patients with ischemic admitted via Emergency Department from 2007 2010 who were assigned 1 3436 hospital service...
Innovative strategies are needed to reduce the hypertension epidemic among African Americans. Reach Out was a faith-collaborative, mobile health, randomized, pilot intervention trial of four health components high blood pressure (BP) compared usual care. It designed and tested within community-based participatory research framework Americans recruited randomized from churches in Flint, Michigan. The purpose this study assess feasibility processes. Feasibility assessed by willingness consent...
Although an expanding array of effective treatments has resulted in recent improvement survival patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification prognostic factors remains a priority. We assessed the impact time to progression disease (POD) after first-line therapy among 455 relapsed MCL. Patients were categorized by duration first remission as PRF/POD6, defined progressive during induction or POD within 6 months diagnosis (n = 65; 14%); POD6-24,...
Primary effusion lymphoma (PEL) is an HIV-associated B-cell non-Hodgkin (NHL) caused by Kaposi sarcoma herpesvirus (KSHV). There no validated prognostic model in PEL, and prognosis thought to be poor compared other NHL. We derived the PEL-Prognostic score (PEL-PS) from international real-world training set of 59 patients with PEL who received first-line anthracycline-containing chemotherapy HIV AIDS Malignancy Branch at National Cancer Institute (NCI) United States Center for Chelsea...
Abstract Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants across age groups. Objectives characterize compare practice patterns, prognostic factors for younger (age < 65) older ≥ 65 years). Among 1162 included, 697 465 older. In patients, 2‐year progression free (PFS) overall (OS) rates 79% 92% respectively; blastoid histology, ECOG...
Clinical classification of early dementia and mild cognitive impairment (MCI) is imprecise. We reported previously that molecular imaging MCI with dual amyloid dopamine terminal positron emission tomography differs significantly from expert clinical classification. now report pathological diagnoses in a substantial subset our imaged subjects. Among 36 subjects coming to autopsy, classifications diagnosis were concordant 33 cases (κ = 0.85). This approach enhanced specificity Alzheimer's...
Objective. Sweat collected for testing should have quantity not sufficient (QNS) rate of ≤10% in babies ≤3 months age. Michigan (MI) cystic fibrosis (CF) centers' QNS rates were 12% to 25% 2009. This project was initiated reduce sweat MI. Methods/Steps. (a) Each center's procedures reviewed by a consultant. (b) center received report with recommendations improve rates. (c) Technicians visited other participating centers observe their procedures. Results. A total 778 infants identified as...
Introduction: Bendamustine + rituximab (BR) is frequently utilized as initial treatment for patients (pts) with mantle cell lymphoma (MCL). Following induction BR, the role of maintenance (MR) controversial and practice patterns vary. MR improves overall survival (OS) in younger pts following autologous stem transplantation (ASCT) older R-CHOP. However, a preliminary analysis randomized phase 3 MAINTAIN study revealed neither progression-free (PFS) nor OS benefit versus observation MCL...
<title>Abstract</title> The authors have requested that this preprint be removed from Research Square.
The therapeutic efficacy of donor lymphocyte infusions (DLIs) given after allogeneic hematopoietic cell transplantation (HCT) is limited by risk graft-versus-host disease (GVHD). Post-transplantation cyclophosphamide (PTCy) effectively prevents severe GVHD, but there are data on outcomes DLIs to PTCy-treated patients. We reviewed 162 consecutive patients transplanted between 2015-2022 within the Center for Immuno-Oncology at National Cancer Institute. Of 38 21 22 HCTs, few were associated...
While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of indolent-behaving disease can safely defer treatment. In this subgroup, we evaluated the importance treatment intensity in MCL who initial therapy.Out 1134 from 12 academic centers, analyzed 219 initiated at least 90 days diagnosis. Patients received induction high-dose cytarabine and/or autologous stem transplantation (ASCT) first remission were considered to have intensive (n = 88)...
BackgroundAutologous stem cell transplant (ASCT) is frequently used as a consolidative therapy option after induction treatment in fit patients with mantle lymphoma (MCL) the goal of prolonging initial response duration. Despite recent advances there remains subset who experience early disease relapse ASCT. We examined predictors shortened progression-free survival (PFS) and post-relapse overall (OS) cohort completing ASCT first remission.MethodsWe evaluated MCL treated at 10 US academic...
Background: Early progression (EP) after intensive initial treatment (tx) for mantle cell lymphoma (MCL) is associated with inferior overall survival (OS; Dietrich Ann Oncol 2014), but its impact less tx and the appropriate management of patients EP not understood. We examined outcomes MCL pts stratified by intensity described 2nd line selection on free (PFS) EP. Methods: reviewed clinical data treated between 2000 2017 at 12 centers defined disease within 1 year (y) initiation. OS was as...
Equine infectious anaemia virus (EIAV) causes persistent infection in equines known as EIA. All the members of equidae family are susceptible to and clinical cases EIA have been reported horses, ponies, mules, zebras donkeys. Animals infected with a virulent strain EIAV may develop an acute form disease high viremia. As there no specific pathognomonic signs EIA, demonstration EIAV-specific antibody serum confirms infection. The study was conducted determine prevalence India using agar gel...